Precision oncology

Corporate Presentation
August 2021

REPARE THERAPEUTICS

Disclaimer

Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “potential,” "projects,” “would” and "future" or similar expressions are intended to identify forward-looking statements. Each of these forward-looking statements involves substantial risks and uncertainties that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding the initiation, timing, progress and results of our current and future preclinical studies and clinical trials; the expected timing of program updates and data disclosures; the timing of filing INDs and other regulatory documents; the timing and likelihood of seeking regulatory approval for our product candidates; the competitive landscape for our product candidates; our ability to identify and develop additional product candidates using our SNIPRx platform; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

These forward-looking statements reflect our current beliefs and expectations. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and unexpected litigation or other disputes. These and other risks are described more fully in our filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of our Quarterly Report on Form 10-Q filed with the SEC on August 12, 2021, and other documents we subsequently filed with or furnished to the SEC. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Except as required by law, we assume no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Solely for convenience, the trademarks and trade names in this presentation may be referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto.

REPARE THERAPEUTICS

Leading clinical-stage precision oncology company focused on synthetic lethality

Lead clinical-stage candidate RP-3500, a potential best-in-class ATR inhibitor; currently in Ph1/2 monotherapy and combination therapy



Robust pipeline of SL-based therapeutics; including RP-6306, our PKMYT1 inhibitor currently in Ph1, and our Polθ inhibitor

Proprietary **genome-wide CRISPR-enabled SNIPRx platform**, focused on genomic instability and DNA damage repair



Powerful SL-based approach and proprietary platform provides **differentiated patient selection insights**

Cash, restricted cash and marketable securities of $301 million as of June 30, 2021

REPARE THERAPEUTICS

Experienced team proven in drug discovery and development

Management team

Lloyd M. Segal
President & CEO

McKinsey & Company · CAPRION ACCELERATING PRECISION MEDICINE · PCP

Steve Forte, CPA
Chief financial officer

clementia · APTALIS

Michael Zinda, PhD
Chief scientific officer

AstraZeneca · Lilly

Kim A. Seth, PhD
Head, business & corporate development

Pfizer · Goldman Sachs



Maria Koehler, MD, PhD
Chief medical officer

gsk · Pfizer · AstraZeneca

Cameron Black, Ph.D.
Head, discovery

MERCK · aneqpharma

Laurence Akiyoshi, Ed.D.
EVP, Organizational & Leadership Development

CROWDSTRIKE · CISCO

Scientific founders

Daniel Durocher, PhD
- Developed CRISPR SL platform
- Deep DNA repair knowledge
- Lunenfeld-Tanenbaum Research Institute (LTRI) & professor at University of Toronto

Agnel Sfeir, PhD
- DDR and cancer pathway investigator
- Pioneer in Polθ, genome instability
- NYU Langone Medical Center & associate professor, Skirball Institute

Frank Sicheri, PhD
- Globally recognized structural biologist, expert in eukaryotic cell signaling, drug mechanism of action
- LTRI & professor at University of Toronto

REPARE THERAPEUTICS

Focused on precision oncology for untapped cancer lesions

Focused on 71% untapped target space
(% of tumors)



Focus of precision oncology for 20 years:
Gain of function (targetable; e.g. EGFR)

REPARE THERAPEUTICS

Gain of function (un-targetable; e.g. CCNE1)

Loss of function (no known driver; e.g. BRCA1)

The NEW ENGLAND JOURNAL of MEDICINE

N ENGL J MED 380;25 NEJM.ORG JUNE 20, 2019

"…known cancer targets represent a small minority of strong cancer dependencies … synthetic lethal targets are particularly attractive as new targets…"

REPARE THERAPEUTICS

SNIPRx platform

REPARE THERAPEUTICS

SNIPRx for synthetic lethal ("SL") drug discovery

1. Select tumor lesion of interest
2. Execute SNIPRx® screen campaign
3. Prioritize, select and validate druggable targets
4. Develop potent and selective inhibitors



- **Starts with the patient's unique genetic lesion**
- **Proprietary genome-wide, CRISPR-enabled platform and isogenic cell lines**
  - Optimizes sensitivity, reproducibility
  - Decreases false negatives
- **Finds targets and patient selection markers that others miss**
- **Novel SL targets identified from every campaign completed to-date**

REPARE THERAPEUTICS

SNIPRx campaigns mine targeted genomic instability lesions

Lesion campaigns completed to-date



We have mined an initial 16 largely mutually exclusive tumor lesions representing ~30% of all tumors

REPARE THERAPEUTICS

STEP²: Repare's patient selection advantage enabled by SNIPRx discovery

4 Develop potent and selective inhibitors

5 Perform SNIPRx® Targeted Expansion of Patient Populations (STEP²) screens

6 Conduct clinical trials in an enriched patient population



STEP² screens: SNIPRx Targeted Expansion of Patient Populations

- **Expands patient populations** beyond those identified by original SL pair
- STEP² insights **enable precision medicine-driven clinical trials**

REPARE THERAPEUTICS

Bristol Myers Squibb – SNIPRx® target discovery collaboration



Multi-target discovery collaboration with Bristol Myers Squibb to leverage Repare's proprietary SNIPRx® synthetic lethal discovery platform to identify multiple oncology drug candidates

~$65M upfront

Including $50M non-dilutive cash and $15M equity investment

~$3 billion

Potential total milestone payments in addition to royalties (~$300M/program)

Target focused

Includes both small molecule SL targets and "undruggable" targets outside our focus

Discovery only

Repare retains all rights to its clinical and pre-clinical pipeline

REPARE THERAPEUTICS

Robust pipeline of SL-based precision oncology therapeutics



REPARE THERAPEUTICS

ATR inhibitor RP-3500

REPARE THERAPEUTICS

RP-3500: Potential best-in-class ATR inhibitor

Oral ATR inhibitor to treat cancers with DNA Damage Response ("DDR") defects and high replication stress

ATR is a critical DDR protein with a central role in regulation of replication stress

Clinical validation of ATR/ATM SL relationship demonstrated at ASCO 2019

Compelling rationale for ATRi combination therapy with PARPi, radiotherapy and PD-1/L1

RP-3500 differentiation driven by:

- **Enhanced chemical properties (potency and selectivity)**
- **Proprietary patient selection insights to expand addressable patient populations**

REPARE THERAPEUTICS

Mechanism of ATM-ATR synthetic lethality



- **Inhibition of ATR:**
  - **Compromises the stabilization of DNA replication forks**
  - **Is associated with increases in DNA double-strand breaks**
- **SL screens have identified that ATR is SL with ATM**

ATR inhibitors induce cell death in ATM-deficient cancer cells

REPARE THERAPEUTICS

ATRi early human monotherapy POC

BAY1895344: First in-human dose escalation trial in HRD+ tumors

Tumor Responses



Timothy A. Yap et al, Cancer Discovery 2020, DOI: 10.1158/2159-8290.CD-20-0868

Durability of response across multiple tumor types



Durable responses observed in 4 distinct tumor types

Durable responses observed across various tumor types; confirmed responding tumors all had ATM deficiency

REPARE THERAPEUTICS

RP-3500: Potential 'best-in-class' ATR inhibitor

	ADME parameter	AZD6738	BAY1895344	M4344 (VX-803)	RP-3500
Potency	ATR Ki (nM)	0.06	3.8	2.9	**0.02**
	ATR Hela cell potency (IC_{50}, nM)	186	2	6	**1**
	Lovo cell viability (IC_{50}, nM)	377	27	86	**22**
	mTor selectivity ratio in Hela cells	6	20	29	**23**
	Kinase activity outside PIKK family	No	No	Yes	**No**
Metabolism	CYP inh (3A4, 2D6, 2C9, 1A2, 2C19)	all >30	12, 28, 12, >30, >30	17, >30, >30, >30, >30	**all >30**
	Liver microsomes: rat, dog, human Cl_{int} (µL/min/mg)	<11.6, <11.6, <11.6	16, 35, 8.6	-	**77, 7.0, 8.0**
	Hepatocytes: rat, dog, human Cl_{int} (µL/min/10^6cells)	<2.9, na, <2.9	<2.9, na, <2.9	<2.9, <2.9, <2.9	**17.3, <1.0, 1.5**

RP-3500 profile offer the potential for:

- **Increased potency**
- **Improved/similar selectivity**
- **Favorable pre-clinical PK profile**
- **Low potential for clinical drug-drug interactions**

Potential to be best-in-class ATRi*

* RP-3500 has not been assessed in head-to-head preclinical studies with AZD6738 or M4344

Preclinical data: RP-3500 vs competitor in animal models

Statistically significant tumor growth suppression in colon cancer model





Higher suppression of tumor growth was observed with RP-3500 as compared to BAY1895344

REPARE THERAPEUTICS

STEP^2 yields biologically relevant hypotheses we are addressing clinically

STEP^2 gene alterations prevent tumor cell recovery from ATR inhibition

Elevate replication stress, increasing the vulnerability of tumor cells to ATRi

RNASEH2A RNASEH2B CHTF8



Disrupt the tumor cells' ability to repair broken DNA, preventing recovery from ATRi

ATM MRE11/NBN/RAD50 BRCA1 BRCA2 PALB2 RAD51B SETD2 CDK12 ATRIP RAD17 FZR1

STEP^2 gene alterations disrupt biological processes relevant to ATRi

REPARE THERAPEUTICS

Expanding RP-3500 patient opportunity with STEP^2 selection tools*

Top 10 tumor types with highest prevalence of ATM deficiency



Top 10 tumor types with highest prevalence of ATM deficiency or STEP^2 genomic alterations



- Beyond ATM, **16 of 19 additional, mutually exclusive genomic alterations identified as SL with RP-3500 are eligible for recruitment into the ongoing trial**
- Represents **expanded, clinically relevant populations with unmet medical needs**
- **Average prevalence of ~2% (ATM) to ~10% (STEP^2 genes)** across multiple tumors

*** TCGA; Not weighted for tumor prevalence**

REPARE THERAPEUTICS

STEP² approach identifies genes to predict combination response

Significant synergy demonstrated by combination of RP-3500 and PARP inhibitors



Talazoparib: 3 nM
RP-3500: 5 nM



Niraparib: 100 nM
RP-3500: 4 nM

- **Identified tumors with STEP² genes sensitive to the combination of RP-3500 and PARP inhibitors**
- **The activity observed at low doses of RP-3500 and PARPi could lead to efficient anti-tumor activity and potentially address known PARPi toxicities**

Significant new approach to select patients for response to combinations

+/+: Wild Type
-/-: Genomically Altered

REPARE THERAPEUTICS

RP-3500 clinical trial design

Global multicenter study designed for patients with:

- Any recurrent tumor with:
  - ATM loss
  - Loss of any of the additional 16 STEP^2 genes



REPARE THERAPEUTICS

PKMYT1 inhibitor RP-6306

REPARE THERAPEUTICS

RP-6306: First-in-class small molecule program

Oral PKMYT1 inhibitor, serving unmet need in tumors with CCNE1 amplification and other lesions

First in class drug PKMYT1 inhibitor, synthetic lethal in CCNE1 amplified, FBXW7 loss and tumors with other specific alterations

Amplification of CCNE1 drives genome instability; found in many tumor types, including Gyn/GI malignancies

Compelling preclinical anti-tumor activity confirms SL relationship of PKMYT1 and CCNE amplification and FBXW7 alterations

RP-6306 key differentiators include:

- Potent and highly selective
- Proprietary patient selection: CCNE1 amp, FBXW7 loss, other STEP[2] genes
- Combinability with several drug classes

REPARE THERAPEUTICS

CCNE1 amplification drives genome instability



CCNE1-overexpression drives premature entry into S-phase and overloads the DNA replication machinery, resulting in genome instability

REPARE THERAPEUTICS

PKMYT1: Strong hit in a CCNE1-overexpression ("O/E") SL screen



- **Genome-wide CRISPR screen**
- **PKMYT1 was the highest scoring druggable hit**
- **PKMYT1 was also a high scoring hit in the DepMap**

REPARE THERAPEUTICS

What is PKMYT1?



PKMYT1 (also known as Myt1):

- **Membrane-associated serine/threonine protein kinase**
- **Member of WEE1 protein kinase family**
- **Selectively phosphorylates cyclin-dependent kinase 1 (CDK1) – no other known substrates**
- **Negatively regulates the G2/M transition of the cell cycle by inactivating CDK1**
- **Not previously linked to CCNE1 amplification**

REPARE THERAPEUTICS

RP-6306: Potent and selective first-in-class PKMYT1 inhibitor

	Parameter	RP-6306
Potency	Enzyme potency (IC_{50}, nM)	3
	HCC1569 CDK1 T14 phosphorylation (IC_{50}, nM)	20
	HCC1569 cell viability (EC_{50}, nM)	19
	PKMYT1 selectivity over WEE1 (cell-based)	>100-fold
ADME Properties	CYP inh (3A4, 2D6, 2C9, 1A2, 2C19)	all >30 µM
	Hepatocytes: rat, dog, human Cl_{int} (µL/min/10^6cells)	28, <6, <6
	Human plasma protein binding	79%
	Rat PK (%F, $t_{1/2}$)	44%, 2.6h
	Dog PK (%F, $t_{1/2}$)	74%, 5.5h

RP-6306 profile:

- Highly potent and selective inhibitor
- PanLabs Lead Profiling screen on 68 assays showed no significant activity at 10 µM
- No activity (>100 µM) in patch clamp assays for hERG, hNaV1.5, and hCaV1.2 ion channels
- Favorable pre-clinical PK profile
- Low potential for clinical drug-drug interactions

RP-6306 Delivers a selective effect on CCNE1-O/E cells vs. WEE1 inhibition



- **PKMYT1 inhibition results in a 39-fold increase in sensitivity in CCNE1-O/E FT282 cells vs. wild type**
- **WEE1 inhibits both wild type and CCNE1-O/E cells**

REPARE THERAPEUTICS

RP-6306 selectively targets CCNE1-amplified tumor cell lines



Tumor cell lines with CCNE1-Amp are hyper-sensitive to PKMYT1 inhibition compared to cells with normal CCNE1 levels

REPARE THERAPEUTICS

RP-6306 inhibits the growth of multiple CCNE1-amplified xenograft tumors



RP-6306 demonstrates efficacy in CCNE1-amplified tumors and is efficacious at doses well below MTD

REPARE THERAPEUTICS

RP-6306 + Gemcitabine drives regression and is well tolerated

Activity (OVCAR3; CCNE1 CN = 14)



Gemcitabine dosed once a week and RP-6306 dosed twice daily

Activity (Robust regression)



Xenograft tumors continue to regress after cessation of dosing with several mice having no measurable tumor detected

REPARE THERAPEUTICS

RP-6306 STEP^2 screen identifies FBXW7 tumor population



RP-6306 STEP^2 genome-wide chemical genetic screen identifies novel patient populations, including FBXW7 alterations

REPARE THERAPEUTICS

The rationale for targeting FBXW7-mutated tumors with RP-6306



FBXW7:

- **E3 ubiquitin ligase that targets proteins, such as CCNE, for proteasomal degradation**
- **Frequently mutated in tumors**
- **Inactivating mutations can increase CCNE levels**
- **STEP[2] screens show that FBXW7 mutations cause sensitivity to PKMYT1 inhibition**

REPARE THERAPEUTICS

RP-6306 inhibits growth of FBXW7 mutant PDX models





- RP-6306 is active across tumor models with clinically relevant hotspot mutations
- Pre-clinical data supports expanding patient populations for RP-6306

REPARE THERAPEUTICS

Potential addressable patient populations with RP-6306

Top 10 tumor types with highest prevalence of CCNE1 amplification and FBXW7 mutations deficiency (Source: TCGA)



FBXW7 and CCNE1 Amplification occur in multiple cancers with significant unmet medical need
These lesions are largely mutually exclusive and represent distinct patient populations

REPARE THERAPEUTICS

RP-6306 clinical program

Targeting tumors with STEP^2 genomic alterations, including CCNE1 amplification and FBXW7 loss

Trial summary & development objectives:

Eligibility:
Any solid tumors with STEP^2 gene alterations per local NGS or FISH + retrospective central confirmation

Early Program Objectives:
1. Safety, tolerability, dose and schedule Phase 1
2. Efficacy in tumors with STEP^2 gene alterations: several Proof of Concept (POC) studies
3. Multiple RP-6306 based combination POC

Global program: North America and Europe

Designed deliver "go" decisions for broader development

Enrollment started Q2 2021

Preliminary data 2022

RP-6306 profile/plan

- Designed to be an orally available ATP- competitive inhibitor
- Maximized potency and specificity
- Genomically defined, tumor-specific and tumor agnostic indications
- Early combination testing

REPARE THERAPEUTICS

RP-6306 initial global clinical trial program

Key inclusion criteria

- Recurrent solid tumors
- CCNE1 amplification, FBXW7 loss and/or other undisclosed RP-6306 STEP^2 alterations



REPARE THERAPEUTICS

Highlights and milestones

REPARE THERAPEUTICS

Financial highlights

$301M

Cash, restricted cash and marketable securities

Balance sheet 30-Jun-2021

Funded through 2022

Expected runway with cash on hand

37.1M

Basic and fully diluted shares outstanding

Shares outstanding 30-Jun-2021

REPARE THERAPEUTICS

Recent progress and upcoming milestones

2020

- Q2: Initial public offering
- Q3: RP-3500 1st patient
- Q4: RP-6306 discovery candidate

2021

- Q1: RP-3500 PARP combination 1st patient
- Q2: RP-6306 1st patient
- Q4: RP-3500 early clinical readouts

2022

- Polθ inhibitor IND enabling studies
- RP-6306 early clinical readouts

REPARE THERAPEUTICS

Repare: Summary of key differentiators

Clinical programs

- RP-3500, potential best-in-class ATR inhibitor with early clinical readouts in early Q4 2021
- RP-6306, second clinical-stage asset, a PKMYT1 inhibitor that entered the clinic this quarter



Pipeline

- Portfolio of assets with 2 clinical SL compounds in ’21
- Multi-target discovery collaboration with Bristol Myers Squibb



Platform

- SNIPRx platform reveals novel insights
- 16+ tumor lesion campaigns complete
- STEP^2 screens enable expanded patient selection tailored to program

Balance sheet

- Funded for multiple key value-creating milestones

REPARE THERAPEUTICS